Targeted sequencing for the molecular diagnosis of diffuse large cell lymphoma B

15 de February de 2017

Institute of Health Carlos III granted the project “Targeted exonic next generation sequencing for the molecular diagnosis and cell free tumor DNA analysis as screening method for patients with DLBCL” in the call for grants Health Research and Development Strategy 2016 File Nº: PI16/01397 with the amount of 98.615€. The research project is led by Dr. Santiago Montes Moreno, a specialist in pathology at the Hospital Universitario Marqués de Valdecilla and head of the IDIVAL Research Group “Cancer Genomics”. Santiago Montes Moreno is a specialist in pathological anatomy at the University Hospital Marqués de Valdecilla and head of the IDIVAL Research Group “Cancer Genomics”.

Cancer Genomics' Group: Soraya Curiel del Olmo, Santiago Montes Moreno,

 Nerea Martínez de Magunacelaya, José Revert Arce y Ainara González

The aim of this Project is to characterize the genetic profile of a selected series of diffuse large B cell lymphoma patient samples by means of targeted exonic next generation sequencing. Diagnostic samples from patients involved in three different clinical trials from GELTAMO group, using novel drugs for targeted lymphoma treatment will be analyzed using a next generation sequencing approach, in order to identify markers associated with response to therapy. In addition to his, we aim to develop a protocol for the accurate and sensitive detection of somatic mutations in the plasma of patients at diagnosis (circulating cell free tDNA). This test may have an application in the screening and follow of patients with DLBCL. 

The project, led by Santiago Montes Moreno is a collaborative effort that involves our Pathology Department in HUMV, Cancer Genomics Lab in IDIVAL, Hospital Universitario de Bellvitge/ICO, Hospital Clinico Universitario de Salamanca and other centers included in the GELTAMO group. Our Institute serves as the reference center for the pathological and molecular diagnosis of patients included in those clinical trials and develops novel molecular diagnosis tools for the better management of DLBCL patients.